AU2001269440A1 - Method for screening mch receptor antagonist/agonist - Google Patents

Method for screening mch receptor antagonist/agonist

Info

Publication number
AU2001269440A1
AU2001269440A1 AU2001269440A AU6944001A AU2001269440A1 AU 2001269440 A1 AU2001269440 A1 AU 2001269440A1 AU 2001269440 A AU2001269440 A AU 2001269440A AU 6944001 A AU6944001 A AU 6944001A AU 2001269440 A1 AU2001269440 A1 AU 2001269440A1
Authority
AU
Australia
Prior art keywords
salt
screening
agonist
slt
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269440A
Inventor
Mioko Harada
Masaaki Mori
Yukio Shimomura
Yasushi Shintani
Tsukasa Sugo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2001269440A1 publication Critical patent/AU2001269440A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a screening method for a compound or a salt thereof that alters the binding property of MCH or a salt thereof to SLT or a salt thereof, or a partial peptide thereof, an amide or an ester thereof, or a salt thereof, characterized by using MCH, a derivative or a salt thereof and SLT or a salt thereof, or a partial peptide thereof, an amide or an ester thereof, or a salt thereof. The screening method of the present invention is useful for screening an SLT agonist, which can be used as an agent for promoting appetite (eating), and an SLT antagonist, which can be used as a prophylactic and/or therapeutic agent for obesity.
AU2001269440A 2000-07-05 2001-07-04 Method for screening mch receptor antagonist/agonist Abandoned AU2001269440A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-208254 2000-07-05
JP2000208254 2000-07-05
PCT/JP2001/005809 WO2002003070A1 (en) 2000-07-05 2001-07-04 Method for screening mch receptor antagonist/agonist

Publications (1)

Publication Number Publication Date
AU2001269440A1 true AU2001269440A1 (en) 2002-01-14

Family

ID=18704874

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269440A Abandoned AU2001269440A1 (en) 2000-07-05 2001-07-04 Method for screening mch receptor antagonist/agonist

Country Status (6)

Country Link
US (1) US7273710B2 (en)
EP (1) EP1298439B1 (en)
AT (1) ATE489626T1 (en)
AU (1) AU2001269440A1 (en)
DE (1) DE60143525D1 (en)
WO (1) WO2002003070A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
US7078187B2 (en) 2001-04-19 2006-07-18 Neurogen Corporation Melanin concentrating hormone receptors
US7078484B2 (en) 2001-04-19 2006-07-18 Neurogen Corporation Melanin concentrating hormone receptors
EP1392298B1 (en) 2001-05-04 2009-02-18 Amgen Inc. Fused heterocyclic compounds
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US7141391B2 (en) 2001-11-13 2006-11-28 Neurogen Corporation Monkey and canine melanin concentrating hormone receptors
CN1330651C (en) 2002-11-06 2007-08-08 安姆根有限公司 Fused heterocyclic compounds
JP4593639B2 (en) * 2008-03-04 2010-12-08 株式会社マルハニチロ食品 Peptide-containing feeding regulator

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525178A (en) 1997-12-03 2001-12-11 スミスクライン ビーチャム コーポレーション Method for searching for agonist and antagonist for human 11cb splice variant
ATE354098T1 (en) * 1998-12-28 2007-03-15 Takeda Pharmaceutical SCREENING PROCEDURE
WO2000049046A1 (en) 1999-02-19 2000-08-24 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
EP1196572A1 (en) 1999-07-27 2002-04-17 Smithkline Beecham Plc Axor21, a g-protein coupled receptor
WO2001036479A1 (en) 1999-11-16 2001-05-25 Merck & Co., Inc. G-protein coupled receptor
JP2003522184A (en) 2000-02-03 2003-07-22 メルク エンド カムパニー インコーポレーテッド Melanin-concentrating hormone analogues
JP2005229804A (en) 2000-03-24 2005-09-02 Astellas Pharma Inc New melanin concentrating hormone receptor

Also Published As

Publication number Publication date
DE60143525D1 (en) 2011-01-05
ATE489626T1 (en) 2010-12-15
EP1298439B1 (en) 2010-11-24
US20040086941A1 (en) 2004-05-06
WO2002003070A1 (en) 2002-01-10
EP1298439A4 (en) 2005-11-23
EP1298439A1 (en) 2003-04-02
US7273710B2 (en) 2007-09-25

Similar Documents

Publication Publication Date Title
WO2003068959A1 (en) Novel screening method
EP1572863A4 (en) Method for identifying inhibitors of g protein coupled receptor signaling
EP2289492A3 (en) Naltrexone hydrochloride compositions
WO2002084286A1 (en) Screening method
WO2002038543A3 (en) 3-substituted oxindole beta 3 agonists
YU84403A (en) Compounds useful as intermediates for derivates-4-aminochinoline
AU2001269440A1 (en) Method for screening mch receptor antagonist/agonist
PL376993A1 (en) Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
AU2003291867A8 (en) Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
SI1440059T1 (en) 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists
EP1572638A4 (en) An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
NO20035413D0 (en) Method of inhibiting calcium salt deposits
EP1581242A4 (en) Compositions and methods for modifying toxic effects of proteinaceous compounds
EP1741792A4 (en) Novel ligand of g-protein-conjugated receptor protein and use thereof
WO2005040157A3 (en) Novel mch receptor antagonists
IL150600A (en) Process for the preparation of compounds containing one or more amide bonds using an excess of an activated carboxylic component and scavenging the residual activated carboxylic component
WO2003065970A3 (en) Treatment of fibromyalgia and related fatigue syndromes using pindolol
IL150824A0 (en) Screening method
WO2002044368A1 (en) Novel g protein-coupled receptor proteins and dnas thereof
WO2003020962A3 (en) Method of identifying glycosyl transferase binding compounds
EP1584925A4 (en) Novel screening method
EP1619499A4 (en) Novel screening method
EP1394543A4 (en) Screening method
WO2003025179A1 (en) Novel polypeptide, dna thereof and use of the same
AU2003290326A1 (en) Compound libraries of 2, 3, 4, 9-tetrahydrospiro (beta-carboline-1, 4 -piperidine) derivatives and related compounds for targetting compounds capable of binding to the g-protein receptor